Company intelligence / Profile preview
Amtix Bio
Seoul, South Koreaamtixbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Amtix Bio is developing innovative first-in-class small molecule drugs targeting microbial virulence factors and related inflammatory pathways for infectious and inflammatory diseases. Its lead asset, ATB1651, is in Phase 2 clinical trials for onychomycosis. Other pipeline programs are in preclinical stages targeting bacterial infections, aspergillosis, inflammatory bowel disease, and infectious lung disorders[1][2][4].
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Amtix Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amtix Bio.